Ligand specificity of the genetic variants of human α1-acid glycoprotein: Generation of a three-dimensional quantitative structure- activity relationship model for drug binding to the a variant

Molecular Pharmacology

Volumn 54, Issue 1, 1998, Pages 129-138

  Hervé, Françoise ^a   Caron, Giulia ^b   Duché, Jean Claude ^a   Gaillard, Patrick ^b   Abd Rahman, Noorsaadah ^b,d   Tsantili Kakoulidou, Anna ^b   Carrupt, Pierre Alain ^b   D'Athis, Philippe ^c   Tillement, Jean Paul ^a   Testa, Bernard ^b  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; BINEDALINE; BORNAPROLOL; CAPSAICIN; CARDIOVASCULAR AGENT; CETIRIZINE; CLOMIPRAMINE; DESIPRAMINE; IMIPRAMINE; ISRADIPINE; MINAPRINE; NEUROLEPTIC AGENT; OROSOMUCOID; PROPAFENONE; PSYCHOTROPIC AGENT; QUINIDINE; STEROID; TERTATOLOL; TRAZODONE; UNINDEXED DRUG; VASODILATOR AGENT; VILOXAZINE; WARFARIN;

ARTICLE; DRUG PROTEIN BINDING; MOLECULAR MODEL; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 0031815338     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.54.1.129     Document Type: Article

References (28)

1. Brunner F and Müller WE (1987) The stereoselectivity of the 'single drug binding site' of human alpha-1-acid glycoprotein (orosomucoid). J Pharm Pharmacol 39:986-990.
2. Bush BL and Nachbar RB Jr (1993) Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J Comput Aided Mol Design 7:587-619.
3. Caron G, Gaillard P, Carrupt PA, and Testa B (1997) Lipophilicity behavior of model and medicinal compounds containing a sulfide, sulfoxide, or sulfone moiety. Helv Chim Acta 80:449-462.
4. Dente L, Pizza MG, Metspalu A, and Cortese R (1987) Structure and expression of the genes coding for human alpha-1-acid glycoprotein. EMBO J 6:2289-2296.
5. Eap CB and Baumann P (1988) Isoelectric focusing of alpha-1-acid glycoprotein (orosomucoid) in immobilized pH gradients with 8 M urea: detection of its desialylated variants using an alkaline phosphatase-linked secondary antibody system. Electrophoresis 9:650-654.
6. Eap CB and Baumann P (1989) The genetic polymorphism of human alpha-1-acid glycoprotein, in Alpha-1-Acid Glycoprotein. Genetics, Biochemistry, Physiological Functions and Pharmacology (Baumann P, Eap CB, Müller WE, and Tillement JP, eds) pp 111-125, Alan R. Liss, New York.
7. Eap CB, Cuendet C, and Baumann P (1990) Binding of d-methadone, l-methadone and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha-1-acid glycoprotein. Clin Pharmacol Ther 47:338-346.
8. Eap CB, Fischer JF, and Baumann P (1991) Variations in relative concentrations of variants of human alpha-1-acid glycoprotein after acute-phase conditions. Clin Chim Acta 203:379-386.
9. Folkers G, Merz A, and Rognan D (1993) CoMFA: scope and limitations, in 3D QSAR in Drug Design: Theory Methods and Applications. (Kubinyi H, ed) pp 583-618, ESCOM Science Publishers, Leiden.
10. Gaillard P, Carrupt PA, Testa B, and Boudon A (1994) Molecular lipophilicity potential, a tool in 3D-QSAR: method and applications. J Comput Aided Mol Design 8:83-96.
11. Gasteiger J and Marsili M (1980) Iterative partial equalization of orbital electronegativity: a rapid access to atomic charges. Tetrahedron 36:3219-3222.
12. Hervé F, Duché JC, Barré J, Millot MC, and Tillement JP (1992) pH titration curves of the desialylated human alpha-1-acid glycoprotein variants by combined isoelectrofocusing-electrophoresis: utilization in the development of a fractionation method for the protein variants by chromatography on immobilized metal affinity adsorbent. J Chromatogr 577:43-59.
13. 1-acid glycoprotein. Pharmacogenetics 6:403-415.
14. Hervé F, Fouache F, Marché C, and Tillement JP (1997) Abnormal microheterogeneity detected in one commercial α1-acid glycoprotein preparation using chromatography on immobilized metal affinity absorbent and on hydroxyapatite. J Chromatogr B 688:35-46.
15. 1-acid glycoprotein in the native form by chromatography on an immobilized copper(II) affinity absorbent: heterogeneity of the separate variants by isoelectrofocusing and by concanavalin A affinity chromatography. J Chromatogr 615:47-57.
16. Hervé F, Gomas E, Duché JC, and Tillement JP (1993b) Evidence for differences in the binding of drugs to the two main genetic variants of human alpha-1-acid glycoprotein. Br J Clin Pharmacol 36:241-249.
17. Kremer JMH, Wilting J, and Janssen LMH (1988) Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 40:1-47.
18. Lima JL, Jungbluth GL, Devine T, and Robertson LW (1984) Stereoselective binding of disopyramide to human plasma proteins. Life Sci 35:835-839.
19. Martin YC, Bures MG, Danaher EA, DeLazzer J, Lico I, and Pavlik PA (1993) A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. J Comput Aided Mol Design 7:83-102.
20. 3 receptor. J Med Chem 37:4109-4117.
21. Raes M, Michiels C, and Remacle J (1987) Comparative study of the enzymatic defense systems against oxygen derived free radicals: the key role of glutathione peroxidase. Free Rad Biol Med 3:3-7.
22. Routledge PA (1986) The plasma protein binding of basic drugs. Br J Clin Pharmacol 22:499-506.
23. Schmid K (1975) Alpha-1-acid glycoprotein, in The Plasma Proteins: Structure, Function and Genetic Control (Putnam FW, ed) pp 183-228, Academic Press, New York.
24. Simon Z (1992) Comparative molecular field analysis: critical comments. Rev Roum Chimie 37:323-325.
25. Tinguely D, Baumann P, Conti M, Jonzier-Perey M, and Schöpf J (1985) Inter individual differences in the binding of antidepressants to plasma proteins: the role of the variants of alpha-1-acid glycoprotein. Eur J Clin Pharmacol 27:661-666.
26. 1-acid glycoprotein (orosomucoid) variants. Hum Genet 84:89-91.
27. Volz M, Mitrovic V, and Schlepper M (1994) Steady-state plasma concentrations of propafenone: chirality and metabolism. Int J Clin Pharmacol Ther 32:370-375.
28. Yuasa I, Weidinger S, Umetsu K, Suenaga K, Ishimoto G, Eap CB, Duché JC, and Baumann P (1993) Orosomucoid system: 17 additional orosomucoid variants and proposal of a new nomenclature. Vox Sang 64:47-55.